Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ONCT 534

X
Drug Profile

ONCT 534

Alternative Names: GTX 534; GTx-534; ONCT-534

Latest Information Update: 30 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Tennessee Research Foundation
  • Developer Oncternal Therapeutics, Inc.
  • Class Antiandrogens; Antineoplastics; Small molecules
  • Mechanism of Action Androgen receptor antagonists; Selective estrogen receptor degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Prostate cancer

Most Recent Events

  • 26 Oct 2023 ONCT 534 receives Fast Track designation for Prostate cancer (Metastatic disease, Second-line therapy or greater, Hormone refractory) in USA
  • 20 Sep 2023 Phase-I/II clinical trials in Prostate cancer (Second-line therapy or greater, Metastatic disease, Hormone refractory) in USA (PO) (NCT05917470)
  • 10 Aug 2023 Oncternal Therapeutics plans a phase I/II clinical study in metastatic castrate-resistant prostate cancer (mCRPC) in the third quarter of 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top